Amaya GM, Barba F, Blancas GF, Gómez FM, Gómez TA, González SR, Hojyo TMT., León DG, López IMM, Moncada B, Orozco TR, Santamaría V

Language: Spanish
References: 53
Page: 172-184
PDF size: 151.28 Kb.

ABSTRACT

Psoriasis is a chronic, immunological disease, the etiology is unknown, just controlled by long medical treatment, non curable, with different types. It is characterized in most of the cases by erythematous, sharply marginated plaques that are the predominant and characteristics injuries. It can have articulate manifestations, well known as Psoriatic arthritis. The 25% to 35% of the patients presents the mild to severe form. The psoriasis affects the patients’ quality of life, which is related to the extension and the intensity of the clinical manifestations. Also, it is able to produce different physical incapacity. The treatment is recently used in stepped form like the Phototherapy, the topical therapy and the systemic. In the cases of severe to mild psoriasis the therapeutic strategy considers the combination of them, or even the three modalities. With the development of investigation in molecular Biology and technology the denominated biological therapy has arisen. The biological therapy has been designed to modulate the key steps in the pathogenesis of the psoriasis. The biological therapy has been evaluated in patients with psoriasis with significant benefits, profiles of satisfaction, tolerability and security, as much as international or national scale. The biological therapy limitation presents/displays within the strategies treatment that definitively is the cost. In the national scope in addition of its cost, is a spreading of the experience developed by specialists with their use, and finally the incorporation of the biological therapy into the clinical guidelines of treatment in psoriasis.

REFERENCES

1. Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999; 26: 723-33.

2. Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the Psoriasis Quality of Life Questionnaire. Dermatol Psychosom 2002; 3: 171-9.

3. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5.

4. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CEM. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000; 142: 728-32.

5. Fortune DG, Main CJ, O’Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis specific stress. Br J Dermatol 1997; 137: 755-60.

6. Zachariae R, Zachariae H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002; 146: 1006-16.

7. Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CEM. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-3.

8. Hermansen SE, Helland CA, Finlay AY. Patients’ and doctors’ assessment of skin disease handicap. Clin Exp Dermatol 2002; 27: 249-50.

9. Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002; 147: 736-42.

10. Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-42.

11. Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CEM. Patients with psoriasis and their compliance with medication. J Am Acad Derm 1999; 41: 581-3.

12. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197(1): 31-6.

13. Yamauchi PS, Rizk D, Kormeili, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003; 49: S66-77.

14. Spuls PI, Witkamp L, Bossuyt PM, et al. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-9

15. Sterry W, Barker J, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. British Journal of Dermatology 2004; 151 (Suppl. 69): 3-17.

16. Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: A personal appraisal of their use in practice. J Am Acad Dermatol 2003; 49: 351-6.

17. Pasic A, Grahovac B, Lipozencic J, Kastelan M, Kostovic K, Ceovic R. The genetics of psoriasis. Acta Dermatovenerol Croat 2004; 12(1): 18-25.

18. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3(2): 121-8.

19. Trujillo IA, Díaz-García MA, Torres-Gemeil O, Torres-Barbosa F, Falcón-Lincheta L, Pérez-Hernández M. Psoriasis Vulgar. Estudio descriptivo de 200 pacientes. Rev Cubana Med 2002; 41(1): 12-5

20. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004 Apr 1; 13 Spec No 1: R43-55.

21. Murak-Kozanecka E, Rabe-Jablonska J. Prevalence and type of dermatologic disorders in psychiatric patients treated with psychotropic drugs. Psychiatr Pol 2004; 38(3): 491-505.

22. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26(4): 314-20.

23. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994; 102(6): 14S-18S.

24. Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000; 66(5): 348-52.

25. Namazi MR. Why is psoriasis uncommon in Africans? The influence of dietary factors on the expression of psoriasis. Int J Dermatol 2004; 43(5): 391-2.

26. Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995; 34(10): 700-3.

27. Lebwohl M, Ali JY. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98.

28. Lauharanta J. Photochemotherapy. Clin Dermatol 1997; 15: 769-80.

29. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464-75.

30. Roenigk HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-85

31. Yamauchi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003; 49: S66-S77.

32. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-80.

33. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.

34. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapad and sustained Benedit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-35.

35. Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003;49(2 Suppl): S78-86.

36. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004; 10(4): 318-25.

37. Yosipovitch G, Tang MB. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging 2002; 19(11): 847-63.

38. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis, the new therapeutic frontier. Arch Dermatol 2002; 138: 657-63.

39. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49(2 Suppl): S112-7.

40. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Sjoqvist U, Lofberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53(6): 849-53

41. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004; 31(8): 1538-45.

42. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004; 31(8): 1532-7.

43. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30(10): 2287-91.

44. Whitmore ES. Appropriate use of alefacept therapy for psoriasis. Arch Dermatol. 2004; 140(2): 239-40.

45. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25(10): 2487-505.

46. Weinberg JM, Tutrone WD. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept. Cutis 2003; 71(1): 41-5.

47. Weinberg JM, Saini R. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. Cutis 2003; 71(1): 25-9.

48. Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004; 50(2): 301-9.

49. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003; 49(2 Suppl): S118-24.

50. van de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol. 2001; 26(4): 356-61.

51. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28(3): 454-9.

52. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol 2004; 3(1): 77-9.

53. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003; 4(9): 1525-33.